Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its audited results for the year ended 31 December 2025. The Group reported revenue growth of 7% (6% in constant currency) to $3.349 billion, compared to $3.127 billion in 2024 with growth in all three geographies, North America, MENA, and Europe. Said Darwazah, […] The post Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes appeared first on Web-Release.
Breaking News:
- ICBA Graduates 21 Arab Women Leaders from AWLA’s Fourth Cohort in Alignment with the International Year of Women Farmers 2026
- e& unveils OneWork for secure sovereign collaboration in the UAE
- LAST CHANCE TO BOOK YOUR STAND AT FOOD SYRIA 2026
- SLC General Secretariat organises workshop on ‘Local Legislative Regulation of Law Enforcement Capacity in Dubai’
- Summer Travel Escapes: Where to Travel This Season
- FCA Signs Four Service-Level Agreements to Advance Integrated Family Care in Abu Dhabi
- Off-Plan Properties Continue to Drive Investor Interest Across Dubai, with Abu Dhabi Emerging as a Key Growth Market
- GEMS Education and Oracle Prepare UAE Students for the AI Economy
Wednesday, June 24